PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Ark Therapeutics Group

6 Feb 2013 11:18

ABERFORTH PARTNERS LLP - Form 8.3 - Ark Therapeutics Group

ABERFORTH PARTNERS LLP - Form 8.3 - Ark Therapeutics Group

PR Newswire

London, February 6

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A

PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Identity of the person whose positions/ Aberforth Partners LLP, on

dealings are being disclosed: behalf of discretionary clients. (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient (c) Name of offeror/offeree in relation to Ark Therapeutics Group plc whose relevant securities this form relates: Use a separate form for each offeror/offeree (d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: 05 February 2013 (f) Has the discloser previously disclosed, or Y/N NO are they today disclosing, under the Code in respect of any other party to this offer? If YES, specify which:

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a) Interests and short positions in the relevant securities of the offeror orofferee to which the disclosure relates following the dealing (if any)

Class of relevant security: Ordinary Shares Interests Short positions Number % Number % (1) Relevant securities owned 28,860,092 13.79 0 0.0 and/or controlled: (2) Derivatives (other than options): (3) Options and agreements to purchase/sell: TOTAL: 28,860,092 13.79 0 0.0

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchaseor sell relevant securities, should be given on a Supplemental Form 8 (OpenPositions).

(b) Rights to subscribe for new securities (including directors' and otherexecutive options)

Class of relevant security in N/A relation to which subscription right exists: Details, including nature of the N/A rights concerned and relevant percentages:

If there are positions or rights to subscribe to disclose in more than oneclass of relevant securities of the offeror or offeree named in 1(c), copytable 2(a) or (b) (as appropriate) for each additional class of relevantsecurity.

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

(a) Purchases and sales

Class of relevant Purchase/sale Number of Price per unit security securities Ordinary Shares Sale 2,915,000 1.009p

(b) Derivatives transactions (other than options)

Class of Product Nature of dealing Number of Price per relevant description reference unit security e.g. opening/closing a securities e.g. CFD long/short position, increasing/reducing a long/short position N/A

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of Product Writing, Number of Exercise Type Expiry Option relevant description purchasing, securities price

date money security e.g. call selling, to which per unit e.g.

paid/

option varying option American, received etc. relates European per unit etc. N/A (ii) Exercising Class of relevant Product Number of Exercise price per security description securities unit e.g. call option N/A

(d) Other dealings (including subscribing for new securities)

Class of relevant Nature of dealing Details Price per unit security (if applicable) e.g. subscription, conversion N/A

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities ofthe offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (asappropriate) for each additional class of relevant security dealt in.

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or

understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person

making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state "none" None

(b) Agreements, arrangements or understandings relating to options orderivatives

Details of any agreement, arrangement or understanding, formal or informal,

between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none" None (c) Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO

Date of disclosure: 06 February 2013 Contact name: David Holland, for Aberforth Partners LLP Telephone number: 0131 220 0733

Public disclosures under Rule 8 of the Code must be made to a RegulatoryInformation Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk . The Panel's Market Surveillance Unit isavailable for consultation in relation to the Code's dealing disclosurerequirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .
Date   Source Headline
1st Mar 201310:50 amRNSForm 8.3 - [Ark Therapeutics]
26th Feb 20135:35 pmRNSHolding(s) in Company
26th Feb 20139:33 amRNSForm 8.3 - Ark Therapeutics Group PLC
25th Feb 201311:55 amRNSForm 8.3 - Ark Therapeutics Group PLC
25th Feb 201311:27 amRNSHolding(s) in Company
22nd Feb 20132:41 pmRNSHolding(s) in Company
21st Feb 20131:24 pmPRNForm 8.3 - Ark Therapeutics plc
21st Feb 201310:56 amRNSHolding(s) in Company
20th Feb 201312:54 pmPRNForm 8.3 - Ark Therapeutics plc
20th Feb 201312:11 pmRNSForm 8.3 - [Ark Therapeutics Group PLC]
19th Feb 20134:40 pmRNSSecond Price Monitoring Extn
19th Feb 20134:35 pmRNSPrice Monitoring Extension
15th Feb 201312:57 pmRNSForm 8.3 - Ark Therapeutics Group PLC
15th Feb 201310:39 amPRNForm 8.3 - Ark Therapeutics Group plc
12th Feb 201312:25 pmRNSHolding(s) in Company
7th Feb 20133:05 pmRNSHolding(s) in Company
7th Feb 20131:41 pmPRNForm 8.3 - Ark Therapeutics Group
6th Feb 20134:43 pmRNSForm 8.3 - Ark Therapeutics
6th Feb 201311:18 amPRNForm 8.3 - Ark Therapeutics Group
6th Feb 201311:02 amRNSForm 8 (OPD)
5th Feb 20134:35 pmRNSPrice Monitoring Extension
5th Feb 20132:48 pmRNSForm 8.3 - Ark Therapeutics Group PLC
4th Feb 20132:43 pmRNSForm 8.3 - Ark Therapeutics Group Plc
4th Feb 20131:10 pmRNSForm 8.3 - Ark Therapeutics
4th Feb 201310:11 amRNSForm 8.3 - [Ark Therapeutics]
1st Feb 20133:10 pmRNSForm 8.3 - Ark Therapeutics Group PLC
1st Feb 20132:53 pmRNSForm 8.3 - Ark Therapeutics Amendment
1st Feb 201312:41 pmRNSForm 8.3 - Ark Therapeutics Group plc
31st Jan 20133:42 pmRNSForm 8.3 - Ark Therapeutics Group PLC
31st Jan 20131:40 pmRNSForm 8.3 - Ark Therapeutics Group Plc
31st Jan 20131:31 pmRNSForm 8.3 - Ark Therapeutics Group plc
31st Jan 201312:02 pmRNSForm 8.3 - ARK Therapeutics plc
31st Jan 201311:51 amBUSForm 8.3 - Ark Therapeutics Group Plc
31st Jan 201311:14 amPRNForm 8.3 - Ark Therapeutics Group
30th Jan 20134:03 pmRNSForm 8.3 - Ark Therapeutics Group Plc
30th Jan 20137:00 amRNSStrategic Review Update
24th Jan 20133:33 pmRNSHolding(s) in Company
21st Jan 20137:00 amRNSCompany Update
4th Dec 20123:40 pmRNSBlocklisting Six Monthly Return
30th Nov 20127:00 amRNSFrench Tax Credit for Research and Development
8th Nov 20127:00 amRNSInterim Management Statement
15th Oct 20127:00 amRNSRe Agreement
26th Sep 20127:00 amRNSManufacturing Agreement Update
29th Aug 20127:00 amRNSHalf Yearly Report
24th Aug 20124:40 pmRNSSecond Price Monitoring Extn
24th Aug 20124:35 pmRNSPrice Monitoring Extension
14th Aug 20127:00 amRNSRe Agreement
25th Jul 20127:00 amRNSManufacturing Partnership
5th Jul 20127:00 amRNSDirectorate Change
11th Jun 20127:00 amRNSAppointment of New Head of Business Development

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.